Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention
Journal of the American College of Cardiology · 2024-11 · 84 (21) · 2073-2084
DOI: 10.1016/j.jacc.2024.08.019 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American College of Cardiology, 2024-11. Verfasst von Renato D Lopes und 15 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: renato.lopes@dm.duke.edu. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Pfizer Inc, Bristol-Myers Squibb Co.
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: Atrial fibrillation (AF) often remains undiagnosed, and it independently raises the risk of ischemic stroke, which is largely reversible by oral anticoagulation. Although randomized trials using longer term screening approaches increase identification of AF, no studies have established that AF screening lowers stroke rates. OBJECTIVES: To address this knowledge gap, the GUARD-AF (Reducing Stroke by Screening for Undiagnosed Atrial Fibrillation in Elderly Individuals) trial screened participants in primary care practices using a 14-day continuous electrocardiographic monitor to determine whether screening for AF coupled with physician/patient decision-making to use oral anticoagulation reduces stroke and provides a net clinical benefit compared with usual care. METHODS: GUARD-AF was a prospective, parallel-group, randomized controlled trial designed to test whether screening for AF in people aged ≥70 years using a 14-day single-lead continuous electrocardiographic patch monitor could identify patients with undiagnosed AF and reduce stroke. Participants were randomized 1:1 to screening or usual care. The primary efficacy and safety outcomes were hospitalization due to all-cause stroke and bleeding, respectively. Analyses used the intention-to-treat population. RESULTS: Enrollment began on December 17, 2019, and involved 149 primary care sites across the United States. The COVID-19 pandemic led to premature termination of enrollment, with 11,905 participants in the intention-to-treat population. Median follow-up was 15.3 months (Q1-Q3: 13.8-17.6 months). Median age was 75 years (Q1-Q3: 72-79 years), and 56.6% were female. The risk of stroke in the screening group was 0.7% vs 0.6% in the usual care group (HR: 1.10; 95% CI: 0.69-1.75). The risk of bleeding was 1.0% in the screening group vs 1.1% in the usual care group (HR: 0.87; 95% CI: 0.60-1.26). Diagnosis of AF was 5% in the screening group and 3.3% in the usual care group, and initiation of oral anticoagulation after randomization was 4.2% and 2.8%, respectively. CONCLUSIONS: In this trial, there was no evidence that screening for AF using a 14-day continuous electrocardiographic monitor in people ≥70 years of age seen in primary care practice reduces stroke hospitalizations. Event rates were low, however, and the trial did not enroll the planned sample size.(Reducing Stroke by Screening for Undiagnosed Atrial Fibrillation in Elderly Individuals [GUARD-AF]; NCT04126486).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: renato.lopes@dm.duke.edu.
- Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.
- Division of Research, Kaiser Permanente Northern California, Oakland, California, USA; Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California, USA; Department of…
- Harvard Medical School, Boston, Massachusetts, USA; Demoulas Center for Cardiac Arrhythmias, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Förderung
- Pfizer Inc
- Bristol-Myers Squibb Co
Zitieren
APA
Lopes, R. D., Atlas, S. J., Go, A. S., Lubitz, S. A., McManus, D. D., Dolor, R. J., Chatterjee, R., Rothberg, M. B., Rushlow, D. R., Crosson, L. A., Aronson, R. S., Patlakh, M., Gallup, D., Mills, D. J., O'Brien, E. C., & Singer, D. E. (2024). Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention. Journal of the American College of Cardiology, 84(21), 2073-2084. https://doi.org/10.1016/j.jacc.2024.08.019
Vancouver
Lopes RD, Atlas SJ, Go AS, Lubitz SA, McManus DD, Dolor RJ, et al. Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention. Journal of the American College of Cardiology. 2024;84(21):2073-2084. doi:10.1016/j.jacc.2024.08.019
BibTeX
@article{Lopes2024,
author = {Lopes, Renato D and Atlas, Steven J and Go, Alan S and Lubitz, Steven A and McManus, David D and Dolor, Rowena J and Chatterjee, Ranee and Rothberg, Michael B and Rushlow, David R and Crosson, Lori A and Aronson, Ronald S and Patlakh, Michael and Gallup, Dianne and Mills, Donna J and O'Brien, Emily C and Singer, Daniel E},
title = {Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention},
journal = {Journal of the American College of Cardiology},
year = {2024},
volume = {84},
number = {21},
pages = {2073--2084},
doi = {10.1016/j.jacc.2024.08.019}
}
EUVIMED